International Vaccine Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1997)

Organization Overview

First Clinical Trial
1998
NCT02556996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Director, Chikungunya Program,International Vaccine Institute | International Vaccince Institute | International Vaccine Insititute | International Vaccine Institute | International Vaccine Institute (IVI), Korea | International Vaccine Institution | Sachin Desai

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chikungunya Fever (Phase 3)

Cholera (Phase 4)

Coronavirus Infections (Phase 2)

Diarrhea (Phase 3)

Fever (Phase 4)

HIV Seropositivity (Phase 2)

Influenza, Human (Phase 1)

Intestinal Diseases (Phase 1)

Paratyphoid Fever (Phase 4)

Poliomyelitis (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Sprue, Tropical (Phase 1)

Typhoid Fever (Phase 4)

Vibrio Infections (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 37